The Neurologist: Clinical & Therapeutics Journal

Editorial Open Access



# Melatonin and Its Role in Neurological Disorders

**Alnicos Docent***

*Unit of Child Neurology and Psychiatry, Department of Human Neuroscience, Sapienza University of Rome, Italy*

## Abstract

Melatonin, a hormone primarily produced by the pineal gland, is well-known for its regulatory role in sleep-wake cycles. However, its influence extends beyond circadian rhythms, with growing evidence suggesting a significant role in various neurological conditions. This paper explores the neuroprotective properties of melatonin and its potential therapeutic applications in neurological disorders such as Alzheimer's disease, Parkinson's disease, stroke, and multiple sclerosis. The molecular mechanisms underlying its effects, including antioxidant, anti-inflammatory, and neurogenesis-promoting actions, are reviewed. Additionally, the challenges and future directions in melatonin-based treatments for neurological diseases are discussed.

**Keywords:** Neurological disorders; Neuroprotection; Alzheimer's disease; Parkinson's disease; Antioxidant; Circadian rhythm; Neuroinflammation; Neurodegeneration

## Introduction

Melatonin, a hormone synthesized in the pineal gland, plays a crucial role in regulating sleep and circadian rhythms. However, emerging research has revealed its broader implications, particularly within the realm of neurology. Beyond its sleep-regulating function, melatonin exhibits potent neuroprotective properties, influencing various biological pathways that are critical for maintaining brain health [1]. These include antioxidant defense, modulation of neuroinflammation, and promotion of neuronal survival. Melatonin's ability to protect against oxidative stress, reduce neuroinflammation, and support neurogenesis makes it a promising candidate for the management of several neurological conditions, including neurodegenerative diseases, ischemic stroke, and even certain psychiatric disorders [2]. This review delves into the latest findings surrounding melatonin's neurological effects, exploring its potential as a therapeutic agent in both clinical and preclinical settings. Understanding the mechanisms of melatonin's action in the brain is essential for developing novel strategies to address the increasing global burden of neurological diseases [3].

## Discussion

Melatonin's neuroprotective properties have garnered significant attention in the context of neurological disorders. The hormone's potent antioxidant capabilities are central to its ability to counteract oxidative stress, a major contributor to neurodegeneration in diseases such as Alzheimer's and Parkinson's. By scavenging free radicals and enhancing the activity of endogenous antioxidants, melatonin helps to mitigate cellular damage in neurons, glial cells, and vascular structures [4]. In addition to its antioxidant properties, melatonin's anti-inflammatory effects play a critical role in protecting the brain from neuroinflammation, which is implicated in the pathophysiology of many neurological conditions. Studies have shown that melatonin can modulate microglial activation and reduce the production of pro-inflammatory cytokines, providing a protective effect against neurodegenerative processes [5-7]. Furthermore, melatonin's influence on mitochondrial function is another essential factor, as it helps maintain cellular energy production, which is vital for optimal brain function. The therapeutic potential of melatonin extends beyond its basic neuroprotective roles. For instance, it has been explored in clinical trials for its efficacy in managing sleep disturbances in patients with neurological disorders. Its ability to regulate circadian rhythms in patients suffering from neurodegenerative diseases has also been highlighted as a potential adjunctive therapy [8]. Additionally, its role in enhancing neurogenesis and promoting neuronal repair after injury or stroke provides a promising avenue for future research.

Despite these promising findings, several challenges remain. The bioavailability of melatonin, optimal dosing, and the best route of administration need to be better defined for its therapeutic application in neurological disorders. Furthermore, while the bulk of research suggests beneficial effects, more extensive human trials are necessary to substantiate the long-term safety and efficacy of melatonin for these conditions [9]. Additionally, while melatonin offers neuroprotective benefits, it is not a cure for neurodegenerative diseases but rather a supportive adjunct that can complement existing treatments. The precise molecular mechanisms underlying its effects remain an area of ongoing investigation [10]. Understanding how melatonin interacts with other signaling pathways in the brain, particularly in the context of disease, will be crucial for designing targeted therapies.

## Conclusion

Melatonin holds significant promise as a neuroprotective agent with potential therapeutic applications in a range of neurological disorders. Its antioxidant, anti-inflammatory, and neurogenesis-promoting actions make it a versatile candidate for preventing and managing diseases such as Alzheimer's, Parkinson's, and stroke-related brain injuries. Although the available evidence supports its efficacy, further research, particularly well-designed clinical trials, is essential to fully establish the role of melatonin in clinical practice. With continued investigation, melatonin may become a valuable tool in the management of neurological diseases, offering hope for patients and providing an avenue for adjunctive therapies that can improve quality

***Corresponding author:** Alnicos Docent, Unit of Child Neurology and Psychiatry, Department of Human Neuroscience, Sapienza University of Rome, Italy, E-mail: alnicosdocent2@gmail.com

**Received:** 01-Jan-2025, Manuscript No: nctj-25-162317, **Editor assigned:** 03-Jan-2025, Pre QC No: nctj-25-162317 (PQ), **Reviewed:** 18-Jan-2025, QC No: nctj-25-162317, **Revised:** 25- Jan-2025, Manuscript No: nctj-25-162317 (R), **Published:** 30- Jan-2025, DOI: 10.4172/nctj.1000244

**Citation:** Alnicos D (2025) Melatonin and Its Role in Neurological Disorders. Neurol Clin Therapeut J 9: 244.

of life and slow disease progression.

## Acknowledgement

None

## Conflict of Interest

None

## References

1. Ackerley S, Kalli A, French S, Davies KE, Talbot K, et al. (2006) A mutation in the small heat-shock protein HSPB1 leading to distal hereditary motor neuronopathy disrupts neurofilament assembly and the axonal transport of specific cellular cargoes. Hum. Mol. Genet 15: 347-354.
2. Penttilä S, Jokela M, Bouquin H, Saukkonen AM, Toivanen J, et al. (2015) Late onset spinal motor neuronopathy is caused by mutation in CHCHD 10 Ann. Neurol. 77: 163-172.
3. Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B, et al. (2000) Htra2-β1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proceedings of the PNAS 97: 9618-9623.
4. Simic G (2008) Pathogenesis of proximal autosomal recessive spinal muscular atrophy. Acta Neuropathol 116: 223-234.
5. Vitali T, Sossi V, Tiziano F, Zappata S, Giuli A, et al. (1999) Detection of the survival motor neuron (SMN) genes by FISH: further evidence for a role for SMN2 in the modulation of disease severity in SMA patients. Hum. Mol 8: 2525-2532.
6. Steege GV, Grootscholten PM, Cobben JM, Zappata S, Scheffer H, et al. (1996) Apparent gene conversions involving the SMN gene in the region of the spinal muscular atrophy locus on chromosome 5. Am J Hum Genet 59: 834-838.
7. Jędrzejowska M, Borkowska J, Zimowsk J, Kostera-Pruszczyk A, Milewski M, et al. (2008) Unaffected patients with a homozygous absence of the SMN1 gene Eur. J. Hum. Genet 16: 930-934.
8. Zheleznyakova GY, Kiselev AV, Vakharlovsky VG, Andersen MR, Chavan R, et al. (2011) Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III. BMC Med Genet 12: 1-9.
9. Prior TW, Swoboda, KJ, Scott HD, Hejmanowski AQ (2004) Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med. Genet 130: 307-310.
10. Helmken C, Hofmann Y, Schoenen F, Oprea G., Raschke H, et al. (2003) Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum Genet 114: 11-21.